Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy (NCT04140162), a na phase 2 study. The primary outcome is Proportion of Participants Who Achieve MRD Negativity Either After Induction or, if Still MRD-positive After Induction, After Consolidation..

2. Clinical Question

3. Trial Design

This phase 2 study evaluates an adaptive treatment strategy for newly diagnosed multiple myeloma. Its registered design is single-group, with allocation listed as not applicable and no masking. The registry record lists enrollment of 57 participants. It does not describe a randomized comparison, and the study should not be read as a head-to-head estimate against a concurrent control group.

The treatment sequence begins with Dara-Rd induction. The arm description specifies induction for all study subjects during weeks 1-24. After induction, MRD-positive participants receive Dara-RVd consolidation during weeks 25-36. The brief summary states that consolidation is given only to participants who remain MRD-positive after induction. Thus, participants do not all receive the same sequence beyond induction; subsequent treatment depends on response status.

The registry record describes maintenance with daratumumab and an additional drug name beginning with L, but the arm description is incomplete at that point. Further maintenance details are not reported in the registry record. The brief summary also says that duration of daratumumab therapy depends on the individual approach, response, evidence of disease progression, and tolerance. A more detailed treatment algorithm is not reported in the registry record.

The primary endpoint is assessed at the end of week 36, after consolidation. The study also lists overall survival, progression-free survival, additional MRD outcomes, and quality-of-life and neurotoxicity assessments. These are intended to describe outcomes beyond the main MRD endpoint, but the registry record does not report results for them. The study status is active, not recruiting.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: 1 subject enrolled, but did not start treatment due to physician discretion.

Induction

Reasons for not completing this period:

Consolidation

Reasons for not completing this period:

Maintenance

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Of 57 enrolled pts, 50 were evaluable for efficacy

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: 1 subject enrolled, but did not start treatment due to physician discretion.

6. Primary Endpoint

The registry lists the primary outcome as Proportion of Participants Who Achieve MRD Negativity Either After Induction or, if Still MRD-positive After Induction, After Consolidation., measured over At the end of week 36 (post-consolidation therapy).

The primary endpoint is the proportion of participants who achieve MRD negativity after induction or, if still MRD-positive after induction, after consolidation. The endpoint is assessed at the end of week 36. The description defines the relevant population as participants completing at least one induction cycle and says MRD status is determined by International Myeloma Working Group response criteria.

This endpoint captures a response state rather than a time-to-event outcome. Its adaptive structure is important to interpretation: participants who are MRD-negative after induction can meet the endpoint without receiving consolidation, while participants who remain MRD-positive can meet it after consolidation. The measure therefore reflects the combined sequence of induction, response assessment, and conditional consolidation, rather than the effect of a single treatment component in isolation.

MRD status provides a way to classify disease response at specified treatment assessments. As a general statistical matter, a binary endpoint such as this is often reported as a count and a proportion, with an uncertainty interval to show how precisely the proportion is estimated. The registry record gives no observed count, proportion, confidence interval, or analysis for the primary endpoint. It therefore does not establish how frequently participants achieved MRD negativity in the posted results.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The design determines which statistical conclusions can be drawn. This is a phase 2, single-group study with no masking and no randomized allocation. In a randomized comparison, treatment groups are formed to support an estimate of the difference between strategies. In a single-group study, outcomes can be described among participants receiving the strategy, but a concurrent randomized contrast is not available. The registry record does not report a separate control group or an adjusted comparison.

What does the primary endpoint estimate?

The primary endpoint is binary: participants either meet the MRD-negativity criterion at the specified assessment sequence or they do not. In general, a binary outcome can be summarized by the number meeting the criterion and the proportion among the defined analysis population. The endpoint’s population description refers to participants completing at least one induction cycle. The record states that 50 participants were evaluable for efficacy, but it does not report the primary endpoint count or proportion. The value of the estimate and its precision therefore cannot be assessed from the posted results.

A confidence interval is a statistical range that expresses uncertainty around an estimate under the assumptions of the analysis. For a binary endpoint, it can show how much uncertainty remains around an estimated proportion. A narrow interval generally indicates greater precision than a wide interval, while neither interval width nor an estimate alone resolves limitations of study design. No primary endpoint confidence interval is reported in the registry record.

How does the adaptive sequence affect the estimand?

As a general concept, an estimand is the specific treatment effect or outcome quantity a study aims to estimate, including the population, treatment condition, outcome, and handling of events after treatment begins. Here, the primary measure is a combined response outcome across induction and conditional consolidation. Participants who are MRD-negative after induction can meet the endpoint at that stage; those who remain positive may receive consolidation and can meet it afterward. This makes the measure relevant to the full adaptive strategy, rather than to consolidation alone. The registry record does not report a separate treatment effect for each component.

The strategy also means treatment exposure is response-dependent. Comparisons between participants who receive consolidation and those who do not would not automatically be like-for-like: receipt of consolidation is determined by post-induction MRD status. A comparison based on those groups could mix treatment effects with differences in response status. No such comparison or adjustment method is reported in the registry record.

What do the planning illustrations mean?

Planning illustrations are not observed trial outcomes and are not observed power. The stated assumptions describe a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The illustrations use a fraction of the observed effect as the effect to detect. For time-to-event outcomes, the stated method uses the total number of events; for other outcomes, it expresses the result as participants per arm.

Those assumptions describe hypothetical planning comparisons, not the registered single-group design. The registry record does not report a trial-specific sample-size justification, the assumed effect used in the original design, or a statistical plan connecting the illustrations to the study protocol. The actual illustration values and an observed effect are not reported in the registry record. Such planning calculations should not be read as evidence that the study had a particular probability of detecting an effect.

Why do event counts need context?

For binary safety outcomes, counts depend on the population at risk and on how events are defined and collected. A percentage listed for an adverse-event term is descriptive; it is not, by itself, a comparison of risk between treatments. For time-to-event outcomes such as overall survival or progression-free survival, interpretation typically depends on follow-up time, event definitions, censoring, and the analysis method. The registry lists these outcomes but does not report their analyses or results.

Over-dispersion is a general issue for count data: it occurs when observed variability exceeds what a simple model assumes. If present, standard uncertainty estimates from an overly restrictive model may be too small. The registry record does not describe a count-data model or an over-dispersion assessment. More broadly, the statistical analysis plan, model specifications, covariate adjustments, interim analyses, and confidence-interval methods are not reported in the registry record.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Dara-Rd Followed by Dara-RVd")
n      <- c(50)
events <- c(15)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Dara-Rd Followed by Dara-RVd  50  15  30.0  17.9  44.6  19.1  43.8  19.1  43.8

11. Multiplicity, Missing Data and Analysis Populations

The registry lists 11 outcome measures, including the primary MRD outcome, survival outcomes, additional MRD outcomes, and quality-of-life and neurotoxicity assessments. It reports 0 analyses. The record therefore does not provide results for the primary or secondary outcomes, or an explanation of how multiple outcomes were handled statistically.

Multiplicity is a general concern when a study evaluates several outcomes or performs repeated hypothesis tests. Testing many questions can increase the chance of at least one apparently notable result even when effects are absent. Common approaches include defining a hierarchy of outcomes, adjusting significance thresholds, or emphasizing estimation and uncertainty rather than treating each test as independent evidence. Which approach, if any, was planned for this study is not reported in the registry record. No adjustment method or testing hierarchy should be assumed.

The efficacy population is described as 50 participants, from 57 enrolled. The primary endpoint description refers to participants who complete at least one cycle of induction. The record does not give participant flow, reasons for non-evaluability, endpoint-specific denominators, or details of missing-data handling. It does not state whether missing assessments were excluded, imputed, or treated by another method. Those omissions limit assessment of possible bias if missingness was related to response, tolerability, disease progression, or other factors.

Analysis populations are also not fully characterized. The registry gives an efficacy-evaluable count but does not describe a full intention-to-treat population, per-protocol population, or safety analysis set. These terms have specific meanings that depend on prespecified rules; they cannot be assigned from the available counts alone. The statistical plan, including any interim analyses or stopping rules, is not reported in the registry record.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: neutrophil count decreased (8.9%), thromboembolic event (5.4%), fever (3.6%), lymphocyte count decreased (3.6%), upper respiratory infection (3.6%).

The registry lists 56 participants at risk for serious adverse events and 25 affected by serious adverse events. It also lists 56 participants at risk for other adverse events and 56 affected. The record lists 5 deaths. These are counts, not estimates of treatment effects, and no comparative group is reported for interpreting them.

The serious adverse-event terms with listed percentages are neutrophil count decreased (8.9%), thromboembolic event (5.4%), fever (3.6%), lymphocyte count decreased (3.6%), upper respiratory infection (3.6%), and lung infection (3.6%). The registry record does not explain whether terms represent participants or event occurrences, whether participants could contribute to more than one term, or the detailed event definitions and attribution rules. The listed percentages should therefore be read as registry summaries, not as mutually exclusive categories or as a basis for calculating an overall event rate.

Adverse events occurring during a trial do not, by themselves, establish that treatment caused them. The record does not provide a control group or a comparative analysis of safety. It also does not report event timing, duration, severity distributions, or the relationship of the listed deaths to treatment. These figures describe what is recorded, but the available information does not support a causal or comparative safety conclusion.

13. What the Result Does, and Does Not, Mean

The study asks whether a response-guided sequence of induction and, when indicated by post-induction MRD positivity, consolidation can result in MRD negativity by the end of week 36. It is a clinically specific question about an adaptive treatment strategy in newly diagnosed multiple myeloma. The registry record describes the treatment sequence and endpoint criteria, but does not report the primary endpoint result.

Without an observed count or proportion, the degree to which participants achieved MRD negativity cannot be quantified from the registry record. Without an uncertainty interval, the precision of any estimate cannot be assessed. The listed enrollment and efficacy-evaluable counts establish the size of those populations, not the response rate. The record also does not describe how missing assessments or participants not evaluable for efficacy were handled.

The single-group design does not provide a randomized comparison with standard of care. The brief summary states a relative-to-standard-of-care objective, but the registry record does not describe a concurrent control group or report a comparison. If outcomes were reported, they could describe results among participants treated according to the study strategy; attributing differences to the strategy would require a suitable comparison and analysis.

The registered secondary outcomes broaden the questions to survival, further MRD status, quality of life, and neurotoxicity. Their presence in the registry does not establish that they were analyzed or that results are available. The record lists 0 analyses. Likewise, safety counts describe recorded events but do not establish causation or comparative risk.

In short, the registry record supports understanding of the study’s design and intended measurements, not a conclusion that the treatment strategy achieved a particular response rate or improved outcomes. Any interpretation of efficacy, precision, comparative benefit, or treatment-related harm would require results and analysis details not reported in the registry record.

14. Why This Trial Matters Statistically

This study is statistically notable because treatment after induction is guided by MRD status. The primary endpoint combines outcomes from participants who become MRD-negative after induction with outcomes from participants who remain positive but may become negative after consolidation. That structure makes the endpoint a measure of the overall adaptive strategy, rather than a simple assessment of one regimen given uniformly to every participant.

It also illustrates a general challenge in response-adapted studies: later treatment depends on an earlier outcome. Participants receiving consolidation are selected because they remain MRD-positive after induction. Their outcomes cannot be compared naively with those of participants who did not need consolidation, since the groups differ by the response that determined treatment. A valid analysis of the strategy needs to define the target question and account for this treatment pathway. The statistical plan is not reported in the registry record.

The endpoint is based on a response classification at a specified time, while the registered secondary outcomes include time-to-event measures and patient-reported assessments. These outcomes have different data structures and require different analysis choices. The registry record lists the measures but does not report the analyses or results, so their estimation and precision cannot be evaluated.

Finally, the registry record distinguishes enrollment from the efficacy-evaluable population but does not explain the difference. This matters because the population contributing to an outcome estimate affects its interpretation. Transparent participant flow, endpoint denominators, missing-data methods, and uncertainty estimates would be needed to assess how robust the response findings are. In this record, the study’s statistical question is clear, but its numerical answer and analytical support are not reported.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpreting this trial record is the absence of posted outcome analyses. The primary endpoint result is not reported, and the record lists 0 analyses. There is therefore no response estimate, uncertainty interval, or inferential result to evaluate. Enrollment and efficacy-evaluable counts cannot substitute for these results.

The study is single-group, unmasked, and has no randomized allocation. The registry record does not describe a concurrent comparator, although the brief summary refers to a relative-to-standard-of-care aim. This limits what can be inferred about comparative effects from the registered design. Results from a single group, if available, would still need to be interpreted in light of the absence of a concurrent control.

The primary endpoint depends on response-guided treatment. Since consolidation is given to participants who remain MRD-positive after induction, outcomes among those receiving consolidation are subject to selection by post-induction response. The record does not report analyses separating induction and consolidation effects or a method for evaluating the strategy as a whole.

Participant accounting is incomplete: 57 participants were enrolled and 50 were evaluable for efficacy, but reasons for non-evaluability and endpoint-specific denominators are not reported. Missing-data rules, analysis populations, and handling of protocol deviations are also not reported in the registry record. These details are important when judging how representative an efficacy estimate would be.

Further limitations include the absence of a reported statistical analysis plan, multiplicity approach, interim-analysis details, and trial-specific sample-size justification. Maintenance details are incomplete in the arm description. Safety information is reported as counts and selected terms without a comparative analysis or enough detail to establish causality. These omissions constrain interpretation of both efficacy and safety.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy — NCT04140162.
• Registry record last updated 2026-07-28; status last verified 2026-07.
• Results first posted 2026-07-28.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes NCT04140162, a phase 2, single-group study of an MRD-driven adaptive strategy for newly diagnosed multiple myeloma. The study uses Dara-Rd induction for all participants, with Dara-RVd consolidation for participants who remain MRD-positive after induction. The primary endpoint is MRD negativity after induction or, if still positive, after consolidation, assessed at the end of week 36.

The record lists 57 enrolled participants and 50 evaluable for efficacy. It lists 11 outcome measures and 0 analyses, and does not report the primary endpoint result. Safety summaries list 25 participants affected by serious adverse events among 56 at risk, 56 affected by other adverse events among 56 at risk, and 5 deaths. The record does not report comparative efficacy analyses, a detailed statistical plan, or detailed handling of missing data.